Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy

Advanced Drug Delivery Reviews

Volumn 61, Issue 5, 2009, Pages 388-401

  Sakaeda, Toshiyuki ^a   Yamamori, Motohiro ^a   Kuwahara, Akiko ^a   Nishiguchi, Kohshi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Chemoradiotherapy; Cisplatin; Esophageal cancer; Genotype guided administration; Pharmacokinetically guided administration

Indexed keywords

5-FLUOROURACIL; CHEMORADIOTHERAPY; CISPLATIN; ESOPHAGEAL CANCER; GENOTYPE-GUIDED ADMINISTRATION; PHARMACOKINETICALLY GUIDED ADMINISTRATION;

PLATINUM COMPOUNDS;

PATIENT TREATMENT;

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; IRINOTECAN;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CONTINUOUS INFUSION; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENETIC POLYMORPHISM; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OTOTOXICITY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; ESOPHAGEAL NEOPLASMS; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 67349101181     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.10.005     Document Type: Review

References (303)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Vizcaino A.P., Moreno V., Lambert R., and Parkin D.M. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int. J. Cancer 99 (2002) 860-868
3. Suntharalingam M., Moughan J., Coia L.R., Krasna M.J., Kachnic L., Haller D.G., Willet C.G., John M.J., Minsky B.D., and Owen J.B. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J. Clin. Oncol. 23 (2005) 2325-2331
4. Trivers K.F., Sabatino S.A., and Stewart S.L. Trends in esophageal cancer incidence by histology, United States, 1998-2003. Int. J. Cancer 123 (2008) 1422-1428
5. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?. Gut 54 Suppl. 1 (2005) i1-i5
6. Pera M., Manterola C., Vidal O., and Grande L. Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 92 (2005) 151-159
7. Shaheen N., and Ransohoff D.F. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA 287 (2002) 1972-1981
8. Holmes R.S., and Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 17 (2007) 2-9
9. Shibata A., Matsuda T., Ajiki W., and Sobue T. Trend in incidence of adenocarcinoma of the esophagus in Japan, 1993-2001. Jpn. J. Clin. Oncol. 38 (2008) 464-468
10. Takubo K., Aida J., Sawabe M., Kurosumi M., Arima M., Fujishiro M., and Arai T. Early squamous cell carcinoma of the oesophagus: the Japanese viewpoint. Histopathology 51 (2007) 733-742
11. Umar S.B., and Fleischer D.E. Esophageal cancer: epidemiology, pathogenesis and prevention. Nat. Clin. Pract. Gastroenterol. Hepatol. 5 (2008) 517-526
12. Blot W.J., and McLaughlin J.K. The changing epidemiology of esophageal cancer. Semin. Oncol. 26 Suppl. 15 (1999) 2-8
13. Garavello W., Negri E., Talamini R., Levi F., Zambon P., Dal Maso L., Bosetti C., Franceschi S., and La Vecchia C. Family history of cancer, its combination with smoking and drinking, and risk of squamous cell carcinoma of the esophagus. Cancer Epidemiol. Biomark. Prev. 14 (2005) 1390-1393
14. Brown L.M., and Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 11 (2002) 235-256
15. Crew K.D., and Neugut A.I. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 31 (2004) 450-464
16. Chow W.H., Blot W.J., Vaughan T.L., Risch H.A., Gammon M.D., Stanford J.L., Dubrow R., Schoenberg J.B., Mayne S.T., Farrow D.C., Ahsan H., West A.B., Rotterdam H., Niwa S., and Fraumeni Jr. J.F. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst. 90 (1998) 150-155
17. Yamaji T., Inoue M., Sasazuki S., Iwasaki M., Kurahashi N., Shimazu T., and Tsugane S. for the Japan Public Health Center-based Prospective Study Group Members of the Japan Public Health Center-based Prospective Study Group, Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: The JPHC study. Int. J. Cancer 123 (2008) 1935-1940
18. Mayne S.T., Risch H.A., Dubrow R., Chow W.H., Gammon M.D., Vaughan T.L., Farrow D.C., Schoenberg J.B., Stanford J.L., Ahsan H., West A.B., Rotterdam H., Blot W.J., and Fraumeni Jr. J.F. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev. 10 (2001) 1055-1062
19. Farrow D.C., Vaughan T.L., Hansten P.D., Stanford J.L., Risch H.A., Gammon M.D., Chow W.H., Dubrow R., Ahsan H., Mayne S.T., Schoenberg J.B., West A.B., Rotterdam H., Fraumeni Jr. J.F., and Blot W.J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev. 7 (1998) 97-102
20. Ye W., Held M., Lagergren J., Engstrand L., Blot W.J., McLaughlin J.K., and Nyrén O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl. Cancer Inst. 96 (2004) 388-396
21. He Y.T., Hou J., Chen Z.F., Qiao C.Y., Song G.H., Meng F.S., Jin H.X., and Chen C. Trends in incidence of esophageal and gastric cardia cancer in high-risk areas in China. Eur. J. Cancer Prev. 17 (2008) 71-76
22. Shimada H., Nabeya Y., Okazumi S., Matsubara H., Shiratori T., Gunji Y., Kobayashi S., Hayashi H., and Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133 (2003) 486-494
23. Buyru N., Tigli H., Duranyildiz D., and Dalay N. Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients. Clin. Chem. Lab. Med. 44 (2006) 538-541
24. Honma H., Kanda T., Ito H., Wakai T., Nakagawa S., Ohashi M., Koyama Y., Valera V.A., Akazawa K., and Hatakeyama K. Squamous cell carcinoma-antigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma. Surgery 139 (2006) 678-685
25. Mroczko B., Kozłowski M., Groblewska M., Łukaszewicz M., Nikliński J., Jelski W., Laudański J., Chyczewski L., and Szmitkowski M. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin. Chim. Acta 389 (2008) 61-66
26. Banki F., Yacoub W.N., Hagen J.A., Mason R.J., Ayazi S., DeMeester S.R., Lipham J.C., Danenberg K., Danenberg P., and DeMeester T.R. Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer. J. Am. Coll. Surg. 207 (2008) 30-35
27. Hashimoto T., Kajiyama Y., Tsutsumi-Ishii Y., Nagaoka I., and Tsurumaru M. Circulating micrometastases of esophageal cancer detected by carcinoembryonic antigen mRNA reverse transcriptase-polymerase chain reaction: clinical implications. Dis. Esophagus 21 (2008) 690-696
28. Kawaguchi H., Ohno S., Miyazaki M., Hashimoto K., Egashira A., Saeki H., Watanabe M., and Sugimachi K. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer 89 (2000) 1413-1417
29. Scheuemann P., Hosch S.B., and Izbicki J.R. Cytokeratins and other sensitive markers for esophageal cancer and metastases. Dis. Esophagus 14 (2001) 85-90
30. Kyrgidis A., Kountouras J., Zavos C., and Chatzopoulos D. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J. Surg. Res. 125 (2005) 189-212
31. Vallböhmer D., and Lenz H.J. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis. Esophagus 19 (2006) 425-432
32. Peters C.J., and Fitzgerald R.C. Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 25 (2007) 1253-1269
33. Yoon H.H., and Forastiere A.A. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncol. 4 (2008) 413-425
34. Ludwig J.A., and Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5 (2005) 845-856
35. Bogoevski D., Onken F., Koenig A., Kaifi J.T., Schurr P., Sauter G., Izbicki J.R., and Yekebas E.F. Is it time for a new TNM classification in esophageal carcinoma?. Ann. Surg. 247 (2008) 633-641
36. Gibault L., Metges J.P., Conan-Charlet V., Lozac'h P., Robaszkiewicz M., Bessaguet C., Lagarde N., and Volant A. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br. J. Cancer 93 (2005) 107-115
37. Gibson M.K., Abraham S.C., Wu T.T., Burtness B., Heitmiller R.F., Heath E., and Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin. Cancer Res. 9 (2003) 6461-6468
38. Miyazono F., Metzger R., Warnecke-Eberz U., Baldus S.E., Brabender J., Bollschweiler E., Doerfler W., Mueller R.P., Dienes H.P., Aikou T., Hoelscher A.H., and Schneider P.M. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br. J. Cancer 91 (2004) 666-672
39. Akamatsu M., Matsumoto T., Oka K., Yamasaki S., Sonoue H., Kajiyama Y., Tsurumaru M., and Sasai K. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 1323-1327
40. Gotoh M., Takiuchi H., Kawabe S., Ohta S., Kii T., Kuwakado S., and Katsu K. Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma. Jpn. J. Clin. Oncol. 37 (2007) 652-657
41. Han B., Liu J., Ma M.J., and Zhao L. Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer. World J. Gastroenterol. 11 (2005) 2188-2192
42. Kuo K.T., Chow K.C., Wu Y.C., Lin C.S., Wang H.W., Li W.Y., and Wang L.S. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann. Thorac. Surg. 76 (2003) 909-914
43. Kulke M.H., Odze R.D., Mueller J.D., Wang H., Redston M., and Bertagnolli M.M. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J. Thorac. Cardiovasc. Surg. 127 (2004) 1579-1586
44. Xi H., Baldus S.E., Warnecke-Eberz U., Brabender J., Neiss S., Metzger R., Ling F.C., Dienes H.P., Bollschweiler E., Moenig S., Mueller R.P., Hoelscher A.H., and Schneider P.M. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin. Cancer Res. 11 (2005) 8341-8347
45. W.Z. Huang, J.H. Fu, D.K. Wang, Y. Hu, M.Z. Liu, H. Yang, Y.F. Feng, B. Zheng, G. Wang, K.J. Luo, J. Wen, T.H. Rong, Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients, Dis. Esophagus 21 (2008) 679-684.
46. Aloia T.A., Harpole Jr. D.H., Reed C.E., Allegra C., Moore M.B., Herndon II J.E., and D'Amico T.A. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann. Thorac. Surg. 72 (2001) 859-866
47. Ikeguchi M., Oka S., Gomyo Y., Tsujitani S., Maeta M., and Kaibara N. Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. Ann. Thorac. Surg. 70 (2000) 913-917
48. Makoto O., Takeda A., Ting-Leig L., Shinnichi O., Hisahiro M., Yutaka F., Yoshihiro N., Kobayashi S., Gunji Y., Suzuki T., Takenori O., and Hideaki S. Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncol. Rep. 9 (2002) 23-28
49. Ikeda G., Isaji S., Chandra B., Watanabe M., and Kawarada Y. Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 86 (1999) 1396-1405
50. Sarbia M., Ott N., Pühringer-Oppermann F., and Brücher B.L. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br. J. Cancer 97 (2007) 1404-1408
51. Sturm I., Petrowsky H., Volz R., Lorenz M., Radetzki S., Hillebrand T., Wolff G., Hauptmann S., Dörken B., and Daniel P.T. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J. Clin. Oncol. 19 (2001) 2272-2281
52. Fujiwara S., Noguchi T., Takeno S., Kimura Y., Fumoto S., and Kawahara K. Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomas. Dis. Esophagus 21 (2008) 125-131
53. Kuwahara M., Hirai T., Yoshida K., Yamashita Y., Hihara J., Inoue H., and Toge T. p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis. Esophagus 12 (1999) 116-119
54. Itami A., Shimada Y., Watanabe G., and Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 57 (1999) 311-317
55. B.L. Brücher, G. Keller, M. Werner, U. Müller, S. Lassmann, A.D. Cabras, F. Fend, R. Busch, H. Stein, H.D. Allescher, M. Molls, J.R. Siewert, H. Höfler, K. Specht, Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy, Int. J. Colorectal. Dis. 24 (2009) 69-77.
56. Nakashima S., Natsugoe S., Matsumoto M., Kijima F., Takebayashi Y., Okumura H., Shimada M., Nakano S., Kusano C., Baba M., Takao S., and Aikou T. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. Anticancer Res. 20 (2000) 1933-1937
57. Sohda M., Ishikawa H., Masuda N., Kato H., Miyazaki T., Nakajima M., Fukuchi M., Manda R., Fukai Y., Sakurai H., and Kuwano H. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int. J. Cancer 110 (2004) 838-844
58. Shamma A., Doki Y., Tsujinaka T., Shiozaki H., Inoue M., Yano M., Kawanishi K., and Monden M. Loss of p27(KIP1) expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 58 (2000) 152-158
59. Chetty R. p27 Protein and cancers of the gastrointestinal tract and liver: an overview. J. Clin. Gastroenterol. 37 (2003) 23-27
60. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon II J.E., Danenberg P.V., and Harpole Jr. D.H. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res. 11 (2005) 2215-2221
61. Warnecke-Eberz U., Metzger R., Miyazono F., Baldus S.E., Neiss S., Brabender J., Schaefer H., Doerfler W., Bollschweiler E., Dienes H.P., Mueller R.P., Danenberg P.V., Hoelscher A.H., and Schneider P.M. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res. 10 (2004) 3794-3799
62. Leichman L., Lawrence D., Leichman C.G., Nava H., Nava E., Proulx G., Clark K., Khushalani N.I., Berdzik J., Greco W., Smith P., Creaven P.J., Kepner J.L., Javle M.M., and Pendyala L. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J. Chemother. 18 (2006) 514-524
63. Terashita Y., Ishiguro H., Haruki N., Sugiura H., Tanaka T., Kimura M., Shinoda N., Kuwabara Y., and Fujii Y. Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer. Oncol. Rep. 12 (2004) 827-831
64. Ikeguchi M., Maeta M., and Kaibara N. Bax expression as a prognostic marker of postoperative chemoradiotherapy for patients with esophageal cancer. Int. J. Mol. Med. 7 (2001) 413-417
65. Takayama T., Nagao M., Sawada H., Yamada Y., Emoto K., Fujimoto H., Ueno M., Hirao S., and Nakajima Y. Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis. J. Surg. Oncol. 78 (2001) 116-123
66. Matsumoto M., Natsugoe S., Nakashima S., Okumura H., Sakita H., Baba M., Takao S., and Aikou T. Clinical significance and prognostic value of apoptosis related proteins in superficial esophageal squamous cell carcinoma. Ann. Surg. Oncol. 8 (2001) 598-604
67. Okumura M., Kajiyama Y., Takeda K., Okumura K., and Tsurumaru M. Correlation between loss of Bcl-X(L) expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy. Eur. Surg. Res. 41 (2008) 260-266
68. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., and Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185 (1998) 256-261
69. Ishibashi Y., Matsumoto T., Niwa M., Suzuki Y., Omura N., Hanyu N., Nakada K., Yanaga K., Yamada K., Ohkawa K., Kawakami M., and Urashima M. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101 (2004) 1994-2000
70. Tanioka Y., Yoshida T., Yagawa T., Saiki Y., Takeo S., Harada T., Okazawa T., Yanai H., and Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br. J. Cancer 89 (2003) 2116-2121
71. Gu Z.D., Li J.Y., Li M., Gu J., Shi X.T., Ke Y., and Chen K.N. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am. J. Gastroenterol. 100 (2005) 1835-1843
72. Yamamoto H., Vinitketkumnuen A., Adachi Y., Taniguchi H., Hirata T., Miyamoto N., Nosho K., Imsumran A., Fujita M., Hosokawa M., Hinoda Y., and Imai K. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis 25 (2004) 2353-2360
73. Sharma R., Chattopadhyay T.K., Mathur M., and Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 67 (2004) 300-309
74. Li S.L., Gao D.L., Zhao Z.H., Liu Z.W., Zhao Q.M., Yu J.X., Chen K.S., and Zhang Y.H. Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J. Gastroenterol. 13 (2007) 6076-6081
75. Deans D.A., Wigmore S.J., Gilmour H., Paterson-Brown S., Ross J.A., and Fearon K.C. Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br. J. Cancer 95 (2006) 1568-1575
76. Abdel-Latif M.M., O'Riordan J., Windle H.J., Carton E., Ravi N., Kelleher D., and Reynolds J.V. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann. Surg. 239 (2004) 491-500
77. Tsunoda S., Okumura T., Ito T., Kondo K., Ortiz C., Tanaka E., Watanabe G., Itami A., Sakai Y., and Shimada Y. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology. 71 (2006) 251-258
78. Takeno S., Noguchi T., Takahashi Y., Fumoto S., Shibata T., and Kawahara K. Assessment of clinical outcome in patients with esophageal squamous cell carcinoma using TNM classification score and molecular biological classification. Ann. Surg. Oncol. 14 (2007) 1431-1438
79. Noguchi T., Takeno S., Shibata T., Uchida Y., Yokoyama S., and Müller W. Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. Ann. Thorac. Surg. 74 (2002) 222-226
80. Griffiths E.A., Pritchard S.A., Valentine H.R., Whitchelo N., Bishop P.W., Ebert M.P., Price P.M., Welch I.M., and West C.M. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br. J. Cancer 96 (2007) 95-103
81. van Baal J.W., and Krishnadath K.K. High throughput techniques for characterizing the expression profile of Barrett's esophagus. Dis. Esophagus 21 (2008) 634-640
82. Daigo Y., and Nakamura Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen. Thorac. Cardiovasc. Surg. 56 (2008) 43-53
83. Kan T., Shimada Y., Sato F., Ito T., Kondo K., Watanabe G., Maeda M., Yamasaki S., Meltzer S.J., and Imamura M. Prediction of lymph node metastasis with use of artificial neural networks based on gene expression profiles in esophageal squamous cell carcinoma. Ann. Surg. Oncol. 11 (2004) 1070-1078
84. Tamoto E., Tada M., Murakawa K., Takada M., Shindo G., Teramoto K., Matsunaga A., Komuro K., Kanai M., Kawakami A., Fujiwara Y., Kobayashi N., Shirata K., Nishimura N., Okushiba S., Kondo S., Hamada J., Yoshiki T., Moriuchi T., and Katoh H. Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin. Cancer Res. 10 (2004) 3629-3638
85. Guo Y., Chen Z., Zhang L., Zhou F., Shi S., Feng X., Li B., Meng X., Ma X., Luo M., Shao K., Li N., Qiu B., Mitchelson K., Cheng J., and He J. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res. 68 (2008) 26-33
86. Qi Y., Chiu J.F., Wang L., Kwong D.L., and He Q.Y. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics 5 (2005) 2960-2971
87. Qi Y.J., He Q.Y., Ma Y.F., Du Y.W., Liu G.C., Li Y.J., Tsao G.S., Ngai S.M., and Chiu J.F. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J. Cell Biochem. 104 (2008) 1625-1635
88. Peng D., Sheta E.A., Powell S.M., Moskaluk C.A., Washington K., Goldknopf I.L., and El-Rifai W. Alterations in Barrett's-related adenocarcinomas: a proteomic approach. Int. J. Cancer 122 (2008) 1303-1310
89. Gulcicek E.E., Colangelo C.M., McMurray W., Stone K., Williams K., Wu T., Zhao H., Spratt H., Kurosky A., and Wu B. Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies. Curr. Protoc. Bioinformatics (2005) Chapter 13
90. Callesen A.K., Christensen R., Madsen J.S., Vach W., Zapico E., Cold S., Jørgensen P.E., Mogensen O., Kruse T.A., and Jensen O.N. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun. Mass Spectrom. 22 (2008) 291-300
91. Ota Y., Takagi Y., Osaka Y., Shinohara M., Hoshino S., Tsuchida A., Aoki T., Honda K., and Yamada T. Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer. Oncol. Rep. 18 (2007) 653-657
92. Koppert L.B., Wijnhoven B.P., van Dekken H., Tilanus H.W., and Dinjens W.N. The molecular biology of esophageal adenocarcinoma. J. Surg. Oncol. 92 (2005) 169-190
93. Schrump D.S., and Nguyen D.M. Novel molecular targeted therapy for esophageal cancer. J. Surg. Oncol. 92 (2005) 257-261
94. Wu D.L., Sui F.Y., Jiang X.M., and Jiang X.H. Methylation in esophageal carcinogenesis. World J. Gastroenterol. 12 (2006) 6933-6940
95. Jackson C., Starling N., Chua Y.J., and Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 67 (2007) 2539-2556
96. Siewert J.R., and Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?. Semin. Radiat. Oncol. 17 (2007) 38-44
97. Stahl M., and Oliveira J. ESMO Guidelines Working Group, Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19 Suppl. 2 (2008) ii21-ii22
98. Khushalani N. Cancer of the esophagus and stomach. Mayo Clin. Proc. 83 (2008) 712-722
99. Yoon H.H., and Forastiere A.A. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncol. 4 (2008) 413-425
100. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
101. Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., and Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335 (1996) 462-467
102. Morita M., Yoshida R., Ikeda K., Egashira A., Oki E., Sadanaga N., Kakeji Y., Yamanaka T., and Maehara Y. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery 143 (2008) 499-508
103. Badwe R.A., Sharma V., Bhansali M.S., Dinshaw K.A., Patil P.K., Dalvi N., Rayabhattanavar S.G., and Desai P.B. The quality of swallowing for patients with operable esophageal carcinoma: a randomized trial comparing surgery with radiotherapy. Cancer 85 (1999) 763-768
104. Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., Estes N., Haller D.G., Ajani J., Kocha W., Minsky B.D., and Roth J.A. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 339 (1998) 1979-1984
105. Bosset J.F., Gignoux M., Triboulet J.P., Tiret E., Mantion G., Elias D., Lozach P., Ollier J.C., Pavy J.J., Mercier M., and Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med. 337 (1997) 161-167
106. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19 (2001) 305-313
107. Lee J.L., Park S.I., Kim S.B., Jung H.Y., Lee G.H., Kim J.H., Song H.Y., Cho K.J., Kim W.K., Lee J.S., Kim S.H., and Min Y.I. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann. Oncol. 15 (2004) 947-954
108. Chiu P.W., Chan A.C., Leung S.F., Leong H.T., Kwong K.H., Li M.K., Au-Yeung A.C., Chung S.C., and Ng E.K. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J. Gastrointest. Surg. 9 (2005) 794-802
109. Burmeister B.H., Smithers B.M., Gebski V., Fitzgerald L., Simes R.J., Devitt P., Ackland S., Gotley D.C., Joseph D., Millar J., North J., Walpole E.T., and Denham J.W. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group, Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 6 (2005) 659-668
110. Jin J., Liao Z., Zhang Z., Ajani J., Swisher S., Chang J.Y., Jeter M., Guerrero T., Stevens C.W., Vaporciyan A., Putnam Jr. J., Walsh G., Smythe R., Roth J., Yao J., Allen P., Cox J.D., and Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 427-436
111. Cooper J.S., Guo M.D., Herskovic A., Macdonald J.S., Martenson Jr. J.A., Al-Sarraf M., Byhardt R., Russell A.H., Beitler J.J., Spencer S., Asbell S.O., Graham M.V., and Leichman L.L. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281 (1999) 1623-1627
112. Herskovic A., Martz K., Al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., Cooper J., Byhardt R., Davis L., and Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326 (1992) 1593-1598
113. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D., and Stroup D.F. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276 (1996) 637-639
114. Al-Sarraf M., Martz K., Herskovic A., Leichman L., Brindle J.S., Vaitkevicius V.K., Cooper J., Byhardt R., Davis L., and Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J. Clin. Oncol. 15 (1997) 277-284
115. Minsky B.D., Pajak T.F., Ginsberg R.J., Pisansky T.M., Martenson J., Komaki R., Okawara G., Rosenthal S.A., and Kelsen D.P. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20 (2002) 1167-1174
116. Minsky B.D. Combined modality therapy for esophageal cancer. Semin. Oncol. 30 4 Suppl 9 (2003) 46-55
117. Brenner B., Ilson D.H., and Minsky B.D. Treatment of localized esophageal cancer. Semin. Oncol. 31 (2004) 554-565
118. Jatoi A., Martenson J.A., Foster N.R., McLeod H.L., Lair B.S., Nichols F., Tschetter L.K., Moore Jr. D.F., Fitch T.R., and Alberts S.R. North Central Cancer Treatment Group (N0044), Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am. J. Clin. Oncol. 30 (2007) 507-513
119. Hsu F.M., Lin C.C., Lee J.M., Chang Y.L., Hsu C.H., Tsai Y.C., Lee Y.C., and Cheng J.C. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J. Surg. Oncol. 98 (2008) 34-41
120. Ilson D.H., Bains M., Kelsen D.P., O'Reilly E., Karpeh M., Coit D., Rusch V., Gonen M., Wilson K., and Minsky B.D. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J. Clin. Oncol. 21 (2003) 2926-2932
121. Anderson S.E., Minsky B.D., Bains M., Hummer A., Kelsen D., and Ilson D.H. Combined modality chemoradiation in elderly oesophageal cancer patients. Br. J. Cancer 96 (2007) 1823-1827
122. Murakami Y., Kenjo M., Uno T., Oguchi M., Shimada M., and Teshima T. Japanese Patterns of Care Study Working Subgroup for Esophageal Cancer, Results of the 1999-2001 Japanese patterns of care study for patients receiving definitive radiation therapy without surgery for esophageal cancer. Jpn. J. Clin. Oncol. 37 (2007) 493-500
123. Safran H., Suntharalingam M., Dipetrillo T., Ng T., Doyle L.A., Krasna M., Plette A., Evans D., Wanebo H., Akerman P., Spector J., Kennedy N., and Kennedy T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 391-395
124. Minsky B.D. Primary combined-modality therapy for esophageal cancer. Oncology (Williston Park). 20 (2006) 497-505
125. Kleinberg L., and Forastiere A.A. Chemoradiation in the management of esophageal cancer. J. Clin. Oncol. 25 (2007) 4110-4117
126. Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J. Oncol. Pharm. Pract. 13 (2007) 207-221
127. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br. J. Clin. Pharmacol. 52 (2001) 75S-87S Suppl 1
128. Bleiberg H., Conroy T., Paillot B., Lacave A.J., Blijham G., Jacob J.H., Bedenne L., Namer M., de Besi P., Gay F., Collette L., and Sahmoud T. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur. J. Cancer 33 (1997) 1216-1220
129. Ohtsu A., Boku N., Muro K., Chin K., Muto M., Yoshida S., Satake M., Ishikura S., Ogino T., Miyata Y., Seki S., Kaneko K., and Nakamura A. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J. Clin. Oncol. 17 (1999) 2915-2921
130. Kaneko K., Ito H., Konishi K., Kurahashi T., Ito T., Katagiri A., Yamamoto T., Kitahara T., Mizutani Y., Ohtsu A., and Mitamura K. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br. J. Cancer 88 (2003) 18-24
131. Hironaka S., Ohtsu A., Boku N., Muto M., Nagashima F., Saito H., Yoshida S., Nishimura M., Haruno M., Ishikura S., Ogino T., Yamamoto S., and Ochiai A. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 425-433
132. Tahara M., Ohtsu A., Hironaka S., Boku N., Ishikura S., Miyata Y., Ogino T., and Yoshida S. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn. J. Clin. Oncol. 35 (2005) 316-323
133. Ishikura S., Nihei K., Ohtsu A., Boku N., Hironaka S., Mera K., Muto M., Ogino T., and Yoshida S. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J. Clin. Oncol. 21 (2003) 2697-2702
134. Kumekawa Y., Kaneko K., Ito H., Kurahashi T., Konishi K., Katagiri A., Yamamoto T., Kuwahara M., Kubota Y., Muramoto T., Mizutani Y., and Imawari M. Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J. Gastroenterol. 41 (2006) 425-432
135. Yamashita H., Nakagawa K., Tago M., Igaki H., Nakamura N., Shiraishi K., Sasano N., and Ohtomo K. The experience of concurrent chemoradiation for Japanese patients with superficial esophageal squamous cell carcinoma: a retrospective study. Am. J. Clin. Oncol. 28 (2005) 555-559
136. Ishida K., Ando N., Yamamoto S., Ide H., and Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn. J. Clin. Oncol. 34 (2004) 615-619
137. Lin Q., Gao X.S., Qiao X.Y., Zhou Z.G., Zhang P., Chen K., Zhao Y.N., and Asaumi J. Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. Acta Med. Okayama 62 (2008) 37-44
138. Muro K., Hamaguchi T., Ohtsu A., Boku N., Chin K., Hyodo I., Fujita H., Takiyama W., and Ohtsu T. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann. Oncol. 15 (2004) 955-959
139. Heath E.I., Urba S., Marshall J., Piantadosi S., and Forastiere A.A. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest. New Drugs. 20 (2002) 95-99
140. Ajani J.A., Ilson D.H., Daugherty K., Pazdur R., Lynch P.M., and Kelsen D.P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J. Natl. Cancer Inst. 86 (1994) 1086-1091
141. Ilson D.H., Forastiere A., Arquette M., Costa F., Heelan R., Huang Y., and Kelsen D.P. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 6 (2000) 316-323
142. Petrasch S., Welt A., Reinacher A., Graeven U., König M., and Schmiegel W. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br. J. Cancer 78 (1998) 511-514
143. Laack E., Andritzky B., Dürk H., Burkholder I., Edler L., Schuch G., Boeters I., Görn M., Lipp R., Horst H., Popp J., and Hossfeld D.K. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 28 (2005) 647-650
144. Adelstein D.J., Rice T.W., Rybicki L.A., Larto M.A., Ciezki J., Saxton J., DeCamp M., Vargo J.J., Dumot J.A., and Zuccaro G. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J. Clin. Oncol. 18 (2000) 2032-2039
145. Hihara J., Yoshida K., Hamai Y., Emi M., Yamaguchi Y., and Wadasaki K. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res. 27 (2007) 2597-2603
146. Jatoi A., Martenson J.A., Foster N.R., McLeod H.L., Lair B.S., Nichols F., Tschetter L.K., Moore Jr. D.F., Fitch T.R., and Alberts S.R. North Central Cancer Treatment Group (N0044), Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am. J. Clin. Oncol. 30 (2007) 507-513
147. Ilson D.H., Ajani J., Bhalla K., Forastiere A., Huang Y., Patel P., Martin L., Donegan J., Pazdur R., Reed C., and Kelsen D.P. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J. Clin. Oncol. 16 (1998) 1826-1834
148. Govindan R., Read W., Faust J., Trinkaus K., Ma M.K., Baker S.D., McLeod H.L., and Perry M.C. Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report. Oncology (Williston Park) 17 9 Suppl 8 (2003) 27-31
149. Ilson D.H., Saltz L., Enzinger P., Huang Y., Kornblith A., Gollub M., O'Reilly E., Schwartz G., DeGroff J., Gonzalez G., and Kelsen D.P. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 17 (1999) 3270-3275
150. Williamson S.K., McCoy S.A., Gandara D.R., Dakhil S.R., Yost K.J., Paradelo J.C., Atkins J.N., Blanke C.D., and Abbruzzese J.L. Southwest Oncology Group (SWOG), Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am. J. Clin. Oncol. 29 (2006) 116-122
151. Urba S.G., Chansky K., van Veldhuizen P.J., Pluenneke R.E., Benedetti J.K., Macdonald J.S., and Abbruzzese J.L. Southwest Oncology Group Study, Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest. New Drugs 22 (2004) 91-97
152. Polee M.B., Kok T.C., Siersema P.D., Tilanus H.W., Splinter T.A., Stoter G., and van der Gaast A. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 12 (2001) 513-517
153. Polee M.B., Hop W.C., Kok T.C., Eskens F.A., van der Burg M.E., Splinter T.A., Siersema P.D., Tilanus H.W., Stoter G., and van der Gaast A. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br. J. Cancer 89 (2003) 2045-2050
154. Conroy T., Etienne P.L., Adenis A., Ducreux M., Paillot B., Oliveira J., Seitz J.F., Francois E., van Cutsem E., Wagener D.J., Kohser F., Daamen S., Praet M., Gorlia T., Baron B., and Wils J. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann. Oncol. 13 (2002) 721-729
155. Koussis H., Scola A., Bergamo F., Tonello S., Basso U., Karahontzitis P., Chiarion-Sileni V., Pasetto L., Ruol A., Loreggian L., Lora O., Bottin R., Marioni G., Donach M., and Jirillo A. Neoadjuvant carboplatin and vinorelbine followed by chemoradiotherapy in locally advanced head and neck or oesophageal squamous cell carcinoma: a phase II study in elderly patients or patients with poor performance status. Anticancer Res. 28 (2008) 1383-1388
156. Bazarbashi S., Rahal M., Raja M.A., El Weshi A., Pai C., Ezzat A., Ajarim D., Memon M., and Al Fadda M. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. Chemotherapy 48 (2002) 211-216
157. Goncalves A., Camerlo J., Bun H., Gravis G., Genre D., Bertucci F., Resbeut M., Pech-Gourg F., Durand A., Maraninchi D., and Viens P. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. 21 (2001) 1431-1437
158. Dhillon S., and Scott L.J. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs 67 (2007) 601-610
159. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am. J. Health Syst. Pharm. 64 9 Suppl 5 (2007) S4-7
160. Lee S.S., Kim S.B., Park S.I., Kim Y.H., Ryu J.S., Song H.Y., Shin J.H., Jung H.Y., Lee G.H., Choi K.D., Cho K.J., and Kim J.H. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer. Jpn. J. Clin. Oncol. 37 (2007) 829-835
161. Czito B.G., Kelsey C.R., Hurwitz H.I., Willett C.G., Morse M.A., Blobe G.C., Fernando N.H., D'Amico T.A., Harpole D.H., Honeycutt W., Yu D., and Bendell J.C. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 1002-1007
162. Tsai J.Y., Iannitti D., Berkenblit A., Akerman P., Nadeem A., Rathore R., Harrington D., Roye D., Miner T., Barnett J.M., Maia C., Stuart K., and Safran H. Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am. J. Clin. Oncol. 28 (2005) 329-333
163. Lee J., Im Y.H., Cho E.Y., Hong Y.S., Lee H.R., Kim H.S., Kim M.J., Kim K., Kang W.K., Park K., and Shim Y.M. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother. Pharmacol. 62 (2008) 77-84
164. Anderson S.E., Minsky B.D., Bains M., Kelsen D.P., and Ilson D.H. Combined modality therapy in esophageal cancer: the Memorial experience. Semin. Surg. Oncol. 21 (2003) 228-232
165. van den Bongard H.J., Mathôt R.A., Beijnen J.H., and Schellens J.H. Pharmacokinetically guided administration of chemotherapeutic agents. Clin. Pharmacokinet. 39 (2000) 345-367
166. Loh G.W., Ting L.S., and Ensom M.H. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin. Pharmacokinet. 46 (2007) 471-494
167. de Jongh F.E., Verweij J., Loos W.J., de Wit R., de Jonge M.J., Planting A.S., Nooter K., Stoter G., and Sparreboom A. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19 (2001) 3733-3739
168. Felici A., Verweij J., and Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer 38 (2002) 1677-1684
169. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol. 14 (1996) 2590-2611
170. Loos W.J., de Jongh F.E., Sparreboom A., de Wit R., van Boven-van Zomeren D.M., Stoter G., Nooter K., and Verweij J. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J. Clin. Oncol. 24 (2006) 1499-1506
171. O'Dwyer P.J., Stevenson J.P., and Johnson S.W. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59 Suppl 4 (2000) 19-27
172. Himmelstein K.J., Patton T.F., Belt R.J., Taylor S., Repta A.J., and Sternson L.A. Clinical kinetics on intact cisplatin and some related species. Clin. Pharmacol. Ther. 29 (1981) 658-664
173. Andersson A., Fagerberg J., Lewensohn R., and Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J. Pharm. Sci. 85 (1996) 824-827
174. Hanada K., Nishijima K., Ogata H., Atagi S., and Kawahara M. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn. J. Clin. Oncol. 31 (2001) 179-184
175. Nagai N., Ogata H., Wada Y., Tsujino D., Someya K., Ohno T., Masuhara K., Tanaka Y., Takahashi H., Nagai H., Kato K., Koshiba Y., Igarashi T., Yokoyama A., Kinameri K., Kato T., and Kurita Y. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J. Clin. Pharmacol. 38 (1998) 1025-1034
176. Salas S., Mercier C., Ciccolini J., Pourroy B., Fanciullino R., Tranchand B., Monjanel-Mouterde S., Baciuchka-Palmaro M., Dupuis C., Yang C., Balti M., Lacarelle B., Duffaud F., Durand A., and Favre R. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther. Drug Monit. 28 (2006) 532-539
177. Urien S., Brain E., Bugat R., Pivot X., Lochon I., Van M.L., Vauzelle F., and Lokiec F. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother. Pharmacol. 55 (2005) 55-60
178. de Jongh F.E., Gallo J.M., Shen M., Verweij J., and Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother. Pharmacol. 54 (2004) 105-112
179. Reece P.A., Stafford I., Russell J., Khan M., and Gill P.G. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J. Clin. Oncol. 5 (1987) 304-309
180. Erdlenbruch B., Nier M., Kern W., Hiddemann W., Pekrun A., and Lakomek M. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur. J. Clin. Pharmacol. 57 (2001) 393-402
181. Nagai N., Kinoshita M., Ogata H., Tsujino D., Wada Y., Someya K., Ohno T., Masuhara K., Tanaka Y., Kato K., Nagai H., Yokoyama A., and Kurita Y. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother. Pharmacol. 39 (1996) 131-137
182. Schellens J.H., Ma J., Planting A.S., van der Burg M.E., van Meerten E., de Boer-Dennert M., Schmitz P.I., Stoter G., and Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73 (1996) 1569-1575
183. Johnsson A., Höglund P., Grubb A., and Cavallin-Ståhl E. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother. Pharmacol. 39 (1996) 25-33
184. Ikeda K., Terashima M., Kawamura H., Takiyama I., Koeda K., Takagane A., Sato N., Ishida K., Iwaya T., Maesawa C., Yoshinari H., and Saito K. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn. J. Clin. Oncol. 28 (1998) 168-175
185. Kurihara N., Kubota T., Hoshiya Y., Otani Y., Ando N., Kumai K., and Kitajima M. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J. Surg. Oncol. 62 (1996) 135-138
186. Beijnen J.H., and Schellens J.H. Drug interactions in oncology. Lancet Oncol. 5 (2004) 489-496
187. Felici A., Loos W.J., Verweij J., Cirillo I., de Bruijn P., Nooter K., Mathijssen R.H., and de Jonge M.J. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. Cancer Chemother. Pharmacol. 58 (2006) 673-680
188. Balis F.M., Holcenberg J.S., and Bleyer W.A. Clinical pharmacokinetics of commonly used anticancer drugs. Clin. Pharmacokinet. 8 (1983) 202-232
189. Diasio R.B., and Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16 (1989) 215-237
190. Powis G. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man. Drug Metab. Rev. 14 (1983) 1145-1163
191. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47 (1987) 2203-2206
192. Coustère C., Mentré F., Sommadossi J.P., Diasio R.B., and Steimer J.L. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother. Pharmacol. 28 (1991) 123-129
193. Gamelin E., Boisdron-Celle M., Guérin-Meyer V., Delva R., Lortholary A., Genevieve F., Larra F., Ifrah N., and Robert J. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 17 (1999) 1105-1110
194. Bocci G., Barbara C., Vannozzi F., Di Paolo A., Melosi A., Barsanti G., Allegrini G., Falcone A., del Tacca M., and Danesi R. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin. Pharmacol. Ther. 80 (2006) 384-395
195. Young A.M., Daryanani S., and Kerr D.J. Can pharmacokinetic monitoring improve clinical use of fluorouracil?. Clin. Pharmacokinet. 36 (1999) 391-398
196. Ploylearmsaeng S.A., Fuhr U., and Jetter A. How may anticancer chemotherapy with fluorouracil be individualised?. Clin. Pharmacokinet. 45 (2006) 567-592
197. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. Clin. Colorectal Cancer 6 (2007) 407-422
198. Gamelin E.C., Danquechin-Dorval E.M., Dumesnil Y.F., Maillart P.J., Goudier M.J., Burtin P.C., Delva R.G., Lortholary A.H., Gesta P.H., and Larra F.G. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77 (1996) 441-451
199. Gamelin E., Boisdron-Celle M., Delva R., Regimbeau C., Cailleux P.E., Alleaume C., Maillet M.L., Goudier M.J., Sire M., Person-Joly M.C., Maigre M., Maillart P., Fety R., Burtin P., Lortholary A., Dumesnil Y., Picon L., Geslin J., Gesta P., Danquechin-Dorval E., Larra F., and Robert J. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol. 16 (1998) 1470-1478
200. Fety R., Rolland F., Barberi-Heyob M., Hardouin A., Campion L., Conroy T., Merlin J.L., Rivière A., Perrocheau G., Etienne M.C., and Milano G. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 4 (1998) 2039-2045
201. Milano G., Etienne M.C., Renée N., Thyss A., Schneider M., Ramaioli A., and Demard F. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol. 12 (1994) 1291-1295
202. Ychou M., Duffour J., Kramar A., Debrigode C., Gourgou S., Bressolle F., and Pinguet F. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother. Pharmacol. 52 (2003) 282-290
203. Di Paolo A., Ibrahim T., Danesi R., Maltoni M., Vannozzi F., Flamini E., Zoli W., Amadori D., and del Tacca M. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther. Drug Monit. 24 (2002) 588-593
204. Trump D.L., Egorin M.J., Forrest A., Willson J.K., Remick S., and Tutsch K.D. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J. Clin. Oncol. 9 (1991) 2027-2035
205. Vokes E.E., Mick R., Kies M.S., Dolan M.E., Malone D., Athanasiadis I., Haraf D.J., Kozloff M., Weichselbaum R.R., and Ratain M.J. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J. Clin. Oncol. 14 (1996) 1663-1671
206. van Groeningen C.J., Pinedo H.M., Heddes J., Kok R.M., de Jong A.P., Wattel E., Peters G.J., and Lankelma J. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48 (1988) 6956-6961
207. Gamelin E., Delva R., Jacob J., Merrouche Y., Raoul J.L., Pezet D., Dorval E., Piot G., Morel A., and Boisdron-Celle M. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26 (2008) 2099-2105
208. Miki I., Tamura T., Nakamura T., Makimoto H., Hamana N., Uchiyama H., Shirasaka D., Morita Y., Yamada H., Aoyama N., Sakaeda T., Okumura K., and Kasuga M. Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther. Drug Monit. 27 (2005) 369-374
209. Okuno T., Tamura T., Yamamori M., Chayahara N., Yamada T., Miki I., Okamura N., Kadowaki Y., Shirasaka D., Aoyama N., Nakamura T., Okumura K., Azuma T., Kasuga M., and Sakaeda T. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am. J. Clin. Oncol. 30 (2007) 252-257
210. Sakaeda T., Yamamori M., Kuwahara A., Hiroe S., Nakamura T., Okumura K., Okuno T., Miki I., Chayahara N., Okamura N., and Tamura T. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther. Drug Monit. 30 (2008) 497-503
211. Altinok A., Lévi F., and Goldbeter A. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery. Adv. Drug Deliv. Rev. 59 (2007) 1036-1053
212. Ohdo S. Circadian rhythms in the CNS and peripheral clock disorders: chronopharmacological findings on antitumor drugs. J. Pharmacol. Sci. 103 (2007) 155-158
213. Bosch T.M., Meijerman I., Beijnen J.H., and Schellens J.H. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45 (2006) 253-285
214. Efferth T., and Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 107 (2005) 155-176
215. Abraham J., Earl H.M., Pharoah P.D., and Caldas C. Pharmacogenetics of cancer chemotherapy. Biochim. Biophys. Acta 1766 (2006) 168-183
216. Auman J.T., and McLeod H.L. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. Drug Metab. Rev. 40 (2008) 303-315
217. Wu X., Lu C., Chiang S.S., and Ajani J.A. Pharmacogenetics in esophageal cancer. Semin. Oncol. 32 6 Suppl 9 (2005) S87-S89
218. Doecke J.D., Zhao Z.Z., Stark M.S., Green A.C., Hayward N.K., Montgomery G.W., Webb P.M., and Whiteman D.C. Australian Cancer Study, Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers. Cancer Epidemiol. Biomark. Prev. 17 (2008) 1007-1012
219. Früh M., Zhou W., Zhai R., Su L., Heist R.S., Wain J.C., Nishioka N.S., Lynch T.J., Shepherd F.A., Christiani D.C., and Liu G. Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma. Br. J. Cancer 98 (2008) 689-692
220. Wu J., Zhang L., Luo H., Zhu Z., Zhang C., and Hou Y. Association of Matrix Metalloproteinases-9 Gene Polymorphisms with Genetic Susceptibility to Esophageal Squamous Cell Carcinoma. DNA Cell Biol. 27 (2008) 553-557
221. Hiyama T., Yoshihara M., Tanaka S., and Chayama K. Genetic polymorphisms and esophageal cancer risk. Int. J. Cancer 121 (2007) 1643-1658
222. Hu N., Wang C., Hu Y., Yang H.H., Giffen C., Tang Z.Z., Han X.Y., Goldstein A.M., Emmert-Buck M.R., Buetow K.H., Taylor P.R., and Lee M.P. Genome-wide association study in esophageal cancer using GeneChip mapping 10 K array. Cancer Res. 65 (2005) 2542-2546
223. Ng D., Hu N., Hu Y., Wang C., Giffen C., Tang Z.Z., Han X.Y., Yang H.H., Lee M.P., Goldstein A.M., and Taylor P.R. Replication of a genome-wide case-control study of esophageal squamous cell carcinoma. Int. J. Cancer 123 (2008) 1610-1615
224. Xie Q., Ratnasinghe LD., Hong H., Perkins R., Tang Z.Z., Hu N., Taylor P.R., and Tong W. Decision forest analysis of 61 single nucleotide polymorphisms in a case-control study of esophageal cancer; a novel method. BMC Bioinformatics 6 Suppl 2 (2005) S4
225. Chen J., Guo L., Peiffer D.A., Zhou L., Chan O.T., Bibikova M., Wickham-Garcia E., Lu S.H., Zhan Q., Wang-Rodriguez J., Jiang W., and Fan J.B. Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. Int. J. Cancer 122 (2008) 2249-2254
226. Yang H.H., Hu N., Taylor P.R., and Lee M.P. Whole genome-wide association study using affymetrix SNP chip: a two-stage sequential selection method to identify genes that increase the risk of developing complex diseases. Methods Mol. Med. 141 (2008) 23-35
227. Giaccone G. Clinical perspectives on platinum resistance. Drugs 59 Suppl 4 (2000) 9-17
228. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33 (2007) 9-23
229. Ye Z., and Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: a systematic review and meta-analysis. Eur. J. Cancer. 41 (2005) 980-989
230. Gatedee J., Pakakassama S., Muangman S., and Pongstaporn W. Glutathione S-transferase P1 genotypes, genetic susceptibility and outcome of therapy in thai childhood acute lymphoblastic leukemia. Asian Pac. J. Cancer Prev. 8 (2007) 294-296
231. Zimniak P., Nanduri B., Pikuła S., Bandorowicz-Pikuła J., Singhal S.S., Srivastava S.K., Awasthi S., and Awasthi Y.C. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224 (1994) 893-899
232. Ali-Osman F., Akande O., Antoun G., Mao J.X., and Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 272 (1997) 10004-10012
233. Abdel-Rahman S.Z., el-Zein R.A., Anwar W.A., and Au W.W. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett. 107 (1996) 229-233
234. Kimura S., Imagawa Y., Satake K., and Tsukuda M. The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma. Int. J. Mol. Med. 14 (2004) 185-189
235. Ishimoto T.M., and Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12 (2002) 543-553
236. Tanner B., Hengstler J.G., Dietrich B., Henrich M., Steinberg P., Weikel W., Meinert R., Kaina B., Oesch F., and Knapstein P.G. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol. Oncol. 65 (1997) 54-62
237. Pasello M., Michelacci F., Scionti I., Hattinger C.M., Zuntini M., Caccuri A.M., Scotlandi K., Picci P., and Serra M. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res. 68 (2008) 6661-6668
238. Joshi M.B., Shirota Y., Danenberg K.D., Conlon D.H., Salonga D.S., Herndon 2nd J.E., Danenberg P.V., and Harpole Jr. D.H. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res. 11 (2005) 2215-2221
239. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., and Kim H.J. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18 (2007) 504-509
240. Ruzzo A., Graziano F., Kawakami K., Watanabe G., Santini D., Catalano V., Bisonni R., Canestrari E., Ficarelli R., Menichetti E.T., Mari D., Testa E., Silva R., Vincenzi B., Giordani P., Cascinu S., Giustini L., Tonini G., and Magnani M. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J. Clin. Oncol. 24 (2006) 1883-1891
241. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., and Stoehlmacher J. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 94 (2006) 281-286
242. Beeghly A., Katsaros D., Chen H., Fracchioli S., Zhang Y., Massobrio M., Risch H., Jones B., and Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol. Oncol. 100 (2006) 330-307
243. Yokomizo A., Yamamoto K., Kinukawa N., Tsunoda T., Koga H., and Naito S. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy. Int. J. Urol. 14 (2007) 500-504
244. Oldenburg J., Kraggerud S.M., Cvancarova M., Lothe R.A., and Fossa S.D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25 (2007) 708-714
245. Booton R., Ward T., Heighway J., Ashcroft L., Morris J., and Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J. Thorac. Oncol. 1 (2006) 679-683
246. Imanishi H., Okamura N., Yagi M., Noro Y., Moriya Y., Nakamura T., Hayakawa A., Takeshima Y., Sakaeda T., Matsuo M., and Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J. Hum. Genet. 52 (2007) 166-171
247. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., and Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J. Clin. Oncol. 25 (2007) 4528-4535
248. Savas S., Kim D.Y., Ahmad M.F., Shariff M., and Ozcelik H. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol. Biomark. Prev. 13 (2004) 801-807
249. Au W.W., Salama S.A., and Sierra-Torres C.H. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ. Health Perspect. 111 (2003) 1843-1850
250. Lunn R.M., Helzlsouer K.J., Parshad R., Umbach D.M., Harris E.L., Sanford K.K., and Bell D.A. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21 (2000) 551-555
251. Spitz M.R., Wu X., Wang Y., Wang L.E., Shete S., Amos C.I., Guo Z., Lei L., Mohrenweiser H., and Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61 (2001) 1354-1357
252. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., Lopez-Vivanco G., Camps C., Botia M., Nuñez L., Sanchez-Ronco M., Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., Artal A., and Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15 (2004) 1194-1203
253. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., and Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61 (2001) 8654-8658
254. Diasio R.B., Beavers T.L., and Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81 (1988) 47-51
255. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47 (1987) 2203-2206
256. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., and Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98 (1996) 610-615
257. Raida M., Schwabe W., Häusler P., van Kuilenburg A.B., van Gennip A.H., Behnke D., and Höffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res. 7 (2001) 2832-2839
258. van Kuilenburg A.B., Muller E.W., Haasjes J., Meinsma R., Zoetekouw L., Waterham H.R., Baas F., Richel D.J., and van Gennip A.H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin. Cancer Res. 7 (2001) 1149-1153
259. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J.H., den Heijer M., Kluijtmans L.A.J., van den Heuve L.P., and Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10 (1995) 111-113
260. Cohen V., Panet-Raymond V., Sabbaghian N., Morin I., Batist G., and Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9 (2003) 1611-1615
261. Sohn K.J., Croxford R., Yates Z., Lucock M., and Kim Y.I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl. Cancer Inst. 96 (2004) 134-144
262. Alberola V., Sarries C., Rosell R., Taron M., de las Peñas R., Camps C., Massuti B., Insa A., Garcia-Gomez R., Isla D., Artal A., Muñoz M.A., Cobo M., Bover I., Gonzalez-Larria J.L., Terrasa J., Almenar D., Barcelo R., Diz P., Sanchez-Ronco M., and Sanchez J.J. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer 5 (2004) 360-365
263. Toffoli G., and de Mattia E. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9 (2008) 1195-1206
264. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.B., Wilke H., and Seeber S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol. 15 (1997) 389-400
265. Bertino J.R., and Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time?. Clin. Cancer Res. 9 (2003) 1235-1239
266. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22 (2004) 529-536
267. Horie N., Aiba H., Oguro K., Hojo H., and Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20 (1995) 191-197
268. Luo H.R., Lü X.M., Yao Y.G., Horie N., Takeishi K., Jorde L.B., and Zhang Y.P. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet. 40 (2002) 41-51
269. Marsh S., Ameyaw M.M., Githang'a J., Indalo A., Ofori-Adjei D., and McLeod H.L. Novel thymidylate synthase enhancer region alleles in African populations. Hum. Mutat. 16 (2000) 528
270. Kawakami K., Graziano F., Watanabe G., Ruzzo A., Santini D., Catalano V., Bisonni R., Arduini F., Bearzi I., Cascinu S., Muretto P., Perrone G., Rabitti C., Giustini L., Tonini G., Pizzagalli F., and Magnani M. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res. 11 (2005) 3778-3783
271. Suh K.W., Kim J.H., Kim Y.B., Kim J., and Jeong S. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J. Gastrointest. Surg. 9 (2005) 336-342
272. Iacopetta B., Grieu F., Joseph D., and Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85 (2001) 827-830
273. Villafranca E., Okruzhnov Y., Dominguez M.A., García-Foncillas J., Azinovic I., Martínez E., Illarramendi J.J., Arias F., Martínez Monge R., Salgado E., Angeletti S., and Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19 (2001) 1779-1786
274. Di Paolo A., and Chu E. The role of thymidylate synthase as a molecular biomarker. Clin. Cancer Res. 10 (2004) 411-412
275. Ulrich C.M., Bigler J., Velicer C.M., Greene E.A., Farin F.M., and Potter J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomark. Prev. 9 (2000) 1381-1385
276. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., and Lenz H.J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91 (2004) 344-354
277. Jakobsen A., Nielsen J.N., Gyldenkerne N., and Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J. Clin. Oncol. 23 (2005) 1365-1369
278. Hitre E., Budai B., Adleff V., Czeglédi F., Horváth Z., Gyergyay F., Lövey J., Kovács T., Orosz Z., Láng I., Kásler M., and Kralovánszky J. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics 15 (2005) 723-730
279. Sarbia M., Stahl M., von Weyhern C., Weirich G., and Pühringer-Oppermann F. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br. J. Cancer 94 (2006) 203-207
280. Liao Z., Liu H., Swisher S.G., Wang L., Wu T.T., Correa A.M., Roth J.A., Cox J.D., Komaki R., Ajani J.A., and Wei Q. Polymorphism at the 3′-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 700-708
281. Mandola M.V., Stoehlmacher J., Muller-Weeks S., Cesarone G., Yu M.C., Lenz H.J., and Ladner R.D. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63 (2003) 2898-2904
282. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
283. Criscuolo G.R., Merrill M.J., and Oldfield E.H. Further characterization of malignant glioma-derived vascular permeability factor. J. Neurosurg. 69 (1988) 254-262
284. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161 (1989) 851-858
285. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J., Siegel N.R., Leimgruber R.M., and Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84 (1989) 1470-1478
286. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246 (1989) 1306-1309
287. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., and Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
288. Olsson A.K., Dimberg A., Kreuger J., and Claesson-Welsh L. VEGF receptor signaling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7 (2006) 359-371
289. Han W., Yu Y., and Liu X.Y. Local signals in stem cell-based bone marrow regeneration. Cell Res. 16 (2006) 189-195
290. Toi M., Matsumoto T., and Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2 (2001) 667-673
291. Takahashi H., and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond) 109 (2005) 227-241
292. Roy H., Bhardwaj S., and Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 580 (2006) 2879-2887
293. Gerber H.P., Malik A.K., Solar G.P., Sherman D., Liang X.H., Meng G., Hong K., Marsters J.C., and Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
294. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Priller J., de Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., and Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8 (2002) 831-840
295. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., Hicklin D.J., Zhu Z., Bohlen P., Witte L., Hendrikx J., Hackett N.R., Crystal R.G., Moore M.A., Werb Z., Lyden D., and Rafii S. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8 (2002) 841-849
296. Yamamori M., Sakaeda T., Nakamura T., Okamura N., Tamura T., Aoyama N., Kamigaki T., Ohno M., Shirakawa T., Gotoh A., Kuroda Y., Matsuo M., Kasuga M., and Okumura K. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem. Biophys. Res. Commun. 325 (2004) 144-150
297. Shahbazi M., Fryer A.A., Pravica V., Brogan I.J., Ramsay H.M., Hutchinson I.V., and Harden P.N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13 (2002) 260-264
298. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., Inoue I., and Katayama S. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51 (2002) 1635-1639
299. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., and Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37 (2000) 443-448
300. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., Paulweber B., Haas J., and Samonigg H. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 106 (2003) 468-471
301. Koukourakis M.I., Papazoglou D., Giatromanolaki A., Bougioukas G., Maltezos E., and Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46 (2004) 293-298
302. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., van Broeckhoven C., Collen D., Andersen P.M., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
303. Prior S.J., Hagberg J.M., Paton C.M., Douglass L.W., Brown M.D., McLenithan J.C., and Roth S.M. DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H1848-1855